Title |
Adenomas in Patients with Inflammatory Bowel Disease Are Associated with an Increased Risk of Advanced Neoplasia
|
---|---|
Published in |
Inflammatory Bowel Diseases, February 2013
|
DOI | 10.1097/mib.0b013e318286f771 |
Pubmed ID | |
Authors |
Fiona D.M. van Schaik, Erik Mooiweer, Mike van der Have, Tim D.G. Belderbos, Fiebo J.W. ten Kate, G. Johan A. Offerhaus, Marguerite E.I. Schipper, Gerard Dijkstra, Marieke Pierik, Pieter C.F. Stokkers, Cyriel Ponsioen, Dirk J. de Jong, Daniel W. Hommes, Ad A. van Bodegraven, Peter D. Siersema, Martijn G.H. van Oijen, Bas Oldenburg |
Abstract |
It is still unclear whether inflammatory bowel disease (IBD) patients with adenomas have a higher risk of developing high-grade dysplasia (HGD) or colorectal cancer (CRC) than non-IBD patients with sporadic adenomas. We compared the risk of advanced neoplasia (AN, defined as HGD or CRC) in IBD patients with adenomas to IBD patients without adenomas and patients without IBD with adenomas. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 19 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 4 | 21% |
Student > Ph. D. Student | 3 | 16% |
Other | 2 | 11% |
Student > Master | 2 | 11% |
Student > Doctoral Student | 1 | 5% |
Other | 4 | 21% |
Unknown | 3 | 16% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 9 | 47% |
Agricultural and Biological Sciences | 3 | 16% |
Immunology and Microbiology | 1 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
Unknown | 5 | 26% |